$RLMD
RELMADA THERAPEUTICS, INC. Stock $rlmd

$rlmd Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000121390022071154 Filed on November 10, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$11.83M	$8.208M	$8.660M
YoY Change	32.83%	-5.22%	45.54%
% of Gross Profit
Research & Development	$26.87M	$30.53M	$33.99M
YoY Change	6.31%	-10.19%	202.44%
% of Gross Profit
Depreciation & Amortization	$0.00	$0.00	$0.00
YoY Change
% of Gross Profit
Operating Expenses	$38.70M	$38.74M	$42.65M
YoY Change	13.22%	-9.18%	148.27%
Operating Profit		-$38.74M	-$42.65M
YoY Change		-9.18%
Interest Expense	$758.1K	-$681.6K	$47.44K
YoY Change	-487.32%	-1536.66%	-83.06%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$681.5K	$47.44K
YoY Change		-1536.53%
Pretax Income	-$37.94M	-$39.42M	-$42.61M
YoY Change	10.37%	-7.48%	152.11%
Income Tax
% Of Pretax Income
Net Earnings	-$37.94M	-$39.42M	-$42.61M
YoY Change	10.37%	-7.48%	152.11%
Net Earnings / Revenue
Basic Earnings Per Share		-$1.31	-$2.44
Diluted Earnings Per Share	-$1.26	-$1.31	-$2.438M
COMMON SHARES
Basic Shares Outstanding	30.10M shares	30.06M shares	17.48M shares
Diluted Shares Outstanding		30.06M shares	17.48M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$148.3M	$184.2M	$88.09M
YoY Change	-30.01%	109.06%	-28.44%
Cash & Equivalents	$5.396M	$42.52M	$11.45M
Short-Term Investments	$142.9M	$141.6M	$76.64M
Other Short-Term Assets	$4.035M	$2.954M	$2.715M
YoY Change	-64.3%	8.77%	23.43%
Inventory
Prepaid Expenses	$4.035M	$2.954M
Receivables
Other Receivables	$512.4K
Total Short-Term Assets	$152.9M	$187.1M	$90.89M
YoY Change	-31.54%	105.87%	-27.58%
LONG-TERM ASSETS
Property, Plant & Equipment			$0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$34.88K	$16.10K	$25.00K
YoY Change	23.26%	-35.62%
Total Long-Term Assets	$34.88K	$16.10K	$47.27K
YoY Change	23.26%	-65.95%	-52.73%
TOTAL ASSETS
Total Short-Term Assets	$152.9M	$187.1M	$90.89M
Total Long-Term Assets	$34.88K	$16.10K	$47.27K
Total Assets	$152.9M	$187.1M	$90.93M
YoY Change	-31.53%	105.78%	-27.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.262M	$10.43M	$12.71M
YoY Change	-52.99%	-17.96%	1715.51%
Accrued Expenses	$7.207M	$10.35M	$5.539M
YoY Change	86.3%	86.89%	105.14%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$12.47M	$20.78M	$18.25M
YoY Change	-17.21%	13.86%	436.69%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.47M	$20.78M	$18.25M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$12.47M	$20.78M	$18.25M
YoY Change	-17.21%	13.86%	436.69%
SHAREHOLDERS EQUITY
Retained Earnings	-$462.1M	-$424.2M
YoY Change	51.48%
Common Stock	$30.10K	$28.64K
YoY Change	8.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$140.4M	$166.3M	$72.69M
YoY Change
Total Liabilities & Shareholders Equity	$152.9M	$187.1M	$90.93M
YoY Change	-31.53%	105.78%	-27.6%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$37.94M	-$39.42M	-$42.61M
YoY Change	10.37%	-7.48%	152.11%
Depreciation, Depletion And Amortization	$0.00	$0.00	$0.00
YoY Change
Cash From Operating Activities	-$35.88M	-$26.86M	-$20.92M
YoY Change	-4.72%	28.43%	67.33%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$1.655M	$31.56M	$27.51M
YoY Change	-98.18%	14.71%	499.37%
Cash From Investing Activities	-$1.655M	$31.56M	$27.51M
YoY Change	-98.18%	14.71%	499.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$185.1K
YoY Change			-88.71%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	409.9K	569.1K	185.1K
YoY Change	-99.75%	207.37%	-88.71%
NET CHANGE
Cash From Operating Activities	-35.88M	-26.86M	-20.92M
Cash From Investing Activities	-1.655M	31.56M	27.51M
Cash From Financing Activities	409.9K	569.1K	185.1K
Net Change In Cash	-37.13M	5.264M	6.780M
YoY Change	-212.53%	-22.37%	-208.13%
FREE CASH FLOW
Cash From Operating Activities	-$35.88M	-$26.86M	-$20.92M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q3	rlmd	Preferred Stock Value1 PreferredStockValue1		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	RELMADA THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-5401931
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2222 Ponce de Leon
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Floor 3
	dei	Entity Address City Or Town EntityAddressCityOrTown	Coral Gables
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33134
	dei	City Area Code CityAreaCode	(786)
	dei	Local Phone Number LocalPhoneNumber	629-1376
	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value per share
	dei	Trading Symbol TradingSymbol	RLMD
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q4	us-gaap	Cash Cash	44443439	usd
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30099203	shares
CY2022Q3	us-gaap	Cash Cash	42524369	usd
CY2022Q3	us-gaap	Short Term Investments ShortTermInvestments	141627805	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	167466167	usd
CY2021Q4	rlmd	Lease Payments Receivable Short Term LeasePaymentsReceivableShortTerm	86377	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2953739	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	11301535	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	187105913	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	223297518	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	16095	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	28293	usd
CY2022Q3	us-gaap	Assets Assets	187122008	usd
CY2021Q4	us-gaap	Assets Assets	223325811	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	10425841	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11192502	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10351312	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3868423	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	20777153	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15060925	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28641991	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28641991	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27740147	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27740147	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	28642	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	27740	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	590482783	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	513304258	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-424166570	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-305067112	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	166344855	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	208264886	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	187122008	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	223325811	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30529108	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33993974	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	86454632	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	65347708	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8208053	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8659661	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	36092024	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26173010	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	38737161	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	42653635	usd
	us-gaap	Operating Expenses OperatingExpenses	122546656	usd
	us-gaap	Operating Expenses OperatingExpenses	91520718	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-38737161	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-42653635	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-122546656	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-91520718	usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	6351606	usd
CY2022Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	827614	usd
CY2021Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	297648	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1544898	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1040429	usd
CY2022Q3	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-561648	usd
CY2021Q3	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-336949	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-552171	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-513328	usd
CY2022Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-947512	usd
CY2021Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	86745	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-3897135	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-379699	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-681546	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	47444	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3447198	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	147402	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-39418707	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-42606191	usd
	us-gaap	Net Income Loss NetIncomeLoss	-119099458	usd
	us-gaap	Net Income Loss NetIncomeLoss	-91373316	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.31
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.44
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.36
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30063735	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17478477	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29470198	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17038583	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	208264886	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	11930681	usd
CY2022Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	29583542	usd
CY2022Q1	rlmd	Warrant Exercised For Cash WarrantExercisedForCash	300006	usd
CY2022Q1	rlmd	Option Exercised For Cash OptionExercisedForCash	64800	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-42606191	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	72687091	usd
CY2022Q2	rlmd	Option Exercised For Cash OptionExercisedForCash	352744	usd
	us-gaap	Net Income Loss NetIncomeLoss	-119099458	usd
CY2022Q2	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	13145057	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-39745783	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	210398132	usd
	us-gaap	Net Income Loss NetIncomeLoss	-91373316	usd
	us-gaap	Depreciation Depreciation	1258	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	12295016	usd
CY2022Q2	rlmd	Warrant Exercised For Cash WarrantExercisedForCash	595350	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	10241599	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	32568836	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	22133630	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-39934968	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	196851331	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	8343139	usd
CY2021Q3	rlmd	Option Exercised For Cash OptionExercisedForCash	52156	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-42014	usd
CY2022Q3	rlmd	Warrant Exercised For Cash WarrantExercisedForCash	332916	usd
CY2022Q3	rlmd	Option Exercised For Cash OptionExercisedForCash	286176	usd
CY2022Q3	rlmd	Venrock Share Exchange Prefunded Warrants Net Of Fees VenrockShareExchangePrefundedWarrantsNetOfFees	50000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-39418707	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	166344855	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	105582746	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	5851284	usd
CY2021Q1	rlmd	Warrant Exercised For Cash WarrantExercisedForCash	1460506	usd
CY2021Q1	rlmd	Option Exercised For Cash OptionExercisedForCash	467773	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-22215181	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	91147128	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	8268376	usd
CY2021Q2	rlmd	Warrant Exercised For Cash WarrantExercisedForCash	481449	usd
CY2021Q2	rlmd	Option Exercised For Cash OptionExercisedForCash	49498	usd
CY2021Q2	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	23458050	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-26551944	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	96852557	usd
CY2021Q3	rlmd	Stock Issued During Period Warrants Issued For License Agreement StockIssuedDuringPeriodWarrantsIssuedForLicenseAgreement	10241599	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	8013970	usd
CY2021Q3	rlmd	Warrant Exercised For Cash WarrantExercisedForCash	175014	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-552171	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-513328	usd
	rlmd	Unrealizedloss Gain On Shortterm Investments UnrealizedlossGainOnShorttermInvestments	-3897135	usd
	rlmd	Unrealizedloss Gain On Shortterm Investments UnrealizedlossGainOnShorttermInvestments	-379699	usd
	us-gaap	Increase Decrease In Leasing Receivables IncreaseDecreaseInLeasingReceivables	-86377	usd
	us-gaap	Increase Decrease In Leasing Receivables IncreaseDecreaseInLeasingReceivables	-58967	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-8359994	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1812288	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-766661	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4362071	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6482889	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1281821	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-67918717	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-54213231	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	38993173	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	82476539	usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	60382229	usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	119541235	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	21389056	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	37064696	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	50000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	42728599	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	23416036	usd
	rlmd	Proceeds From Options Exercised For Common Stock ProceedsFromOptionsExercisedForCommonStock	703720	usd
	rlmd	Proceeds From Options Exercised For Common Stock ProceedsFromOptionsExercisedForCommonStock	569427	usd
	rlmd	Cashless Eexercise Of Warrants CashlessEexerciseOfWarrants	-1228272	usd
	rlmd	Cashless Eexercise Of Warrants CashlessEexerciseOfWarrants	-2116969	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	44610591	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	26102432	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1919070	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	8953897	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	44443439	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2495397	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	42524369	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11449294	usd
	rlmd	Cashless Exercise Of Options For Common Stock CashlessExerciseOfOptionsForCommonStock	1452	usd
	rlmd	Incurred Negative Operating Cash Flows IncurredNegativeOperatingCashFlows	67918717	usd
CY2022Q3	us-gaap	Cumulative Earnings Deficit CumulativeEarningsDeficit	424166570	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	42728599	usd
	rlmd	Equity Offering Cost EquityOfferingCost	703720	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1228272
CY2022Q3	us-gaap	Related Parties Amount In Cost Of Sales RelatedPartiesAmountInCostOfSales	13145057	usd
CY2022Q3	rlmd	Aggregate Offering Price AggregateOfferingPrice	100000000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. The significant estimates are stock-based compensation expenses and recorded amounts related to income taxes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2022Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	42524369	usd
CY2022Q3	us-gaap	Shortterm Debt Fair Value ShorttermDebtFairValue	141627805	usd
CY2022Q3	us-gaap	Other Short Term Investments OtherShortTermInvestments	141627805	usd
CY2022Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-947512	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-3897135	usd
CY2021Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	86745	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-379699	usd
CY2022Q3	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.01	pure
CY2022Q3	us-gaap	Reporting Unit Percentage Of Fair Value In Excess Of Carrying Amount ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount	0.01	pure
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15204298	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8288179	shares
CY2022Q2	us-gaap	General Partners Offering Costs GeneralPartnersOfferingCosts	100000000	usd
CY2022Q3	us-gaap	Prepaid Insurance PrepaidInsurance	478500	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	353300	usd
CY2022Q3	rlmd	Prepaid Research And Development PrepaidResearchAndDevelopment	2415500	usd
CY2021Q4	rlmd	Prepaid Research And Development PrepaidResearchAndDevelopment	10708800	usd
CY2022Q3	rlmd	Prepaid Legal PrepaidLegal	11000	usd
CY2021Q4	rlmd	Prepaid Legal PrepaidLegal	11000	usd
CY2022Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	48700	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	228400	usd
CY2022Q3	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	2953700	usd
CY2021Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	11301500	usd
CY2022Q3	rlmd	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	8058900	usd
CY2021Q4	rlmd	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	1928000	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	172000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	168000	usd
CY2022Q3	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	1182900	usd
CY2021Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	1191000	usd
CY2022Q3	us-gaap	Accrued Vacation Current AccruedVacationCurrent	648300	usd
CY2021Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	450400	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	289200	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	131000	usd
CY2022Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	10351300	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	3868400	usd
CY2020Q2	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	2094243	shares
CY2022Q3	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	175919	shares
	rlmd	Cashless Exercise Of Warrants Value CashlessExerciseOfWarrantsValue	1228272	usd
CY2020Q2	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	42728599	usd
	rlmd	Stock Options Exercisable Period StockOptionsExercisablePeriod	P10Y
CY2014Q4	rlmd	Granting To Option Or Stock Awards GrantingToOptionOrStockAwards	5152942	shares
CY2021Q2	rlmd	Granted Options GrantedOptions	1500000	shares
CY2022Q2	us-gaap	Shares Issued SharesIssued	3900000	shares
CY2022Q3	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	0.001
	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.0999
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	6700000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
	us-gaap	Stockholders Equity Other Shares StockholdersEquityOtherShares	166482	shares
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	121700000	usd
	rlmd	Term Year TermYear	P2Y5M4D
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1452016	shares
CY2022Q3	rlmd	Prefund Warrants prefundWarrants	1452016	shares
CY2022Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1452016	shares
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32568800	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32375200	usd
CY2022Q3	rlmd	Payment For License PaymentForLicense	45000	usd
CY2021Q3	rlmd	License Agreement Description LicenseAgreementDescription	Under the terms of the License Agreement, the Company paid Arbormentis, LLC an upfront fee of $12.7 million, consisting of a mix of cash and warrants to purchase the Company’s common stock, in addition to potential milestone payments totaling up to approximately $160 million related to pre-specified development and commercialization milestones. Arbormentis, LLC is also eligible to receive a low single digit royalty on net sales of any commercialized therapy resulting from this agreement. The license agreement is terminable by the Company but is perpetual and not terminable by the licensor absent material breach of its terms by the Company.
CY2021Q3	us-gaap	Payments For Rent PaymentsForRent	11000	usd
CY2021Q3	rlmd	Lease Period LeasePeriod	P5M
CY2021Q3	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2021-12-31
CY2021Q3	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement		usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement		usd
CY2021Q3	us-gaap	Prepaid Rent PrepaidRent	9000	usd
	rlmd	Lease Expense LeaseExpense	75700	usd
	rlmd	Lease Expense LeaseExpense	87100	usd
	us-gaap	Lease Income LeaseIncome	2500	usd
	us-gaap	Lease Income LeaseIncome	8800	usd
	us-gaap	Description Of Defined Contribution Pension And Other Postretirement Plans DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans	The Company matches 100% of the first 3% of employee contributions, plus 50% of employee contributions that exceed 3% but do not exceed 5%.
	rlmd	Employee Contribution Expense EmployeeContributionExpense	87900	usd
	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	101100	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5417	shares
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	36252	usd
CY2022Q3	rlmd	Lease Payments Receivable Short Term LeasePaymentsReceivableShortTerm		usd
CY2021Q4	rlmd	Preferred Stock Value1 PreferredStockValue1		usd
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.31
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.44
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.36
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17038583	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17478477	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29470198	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30063735	shares
	us-gaap	Depreciation Depreciation		usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	rlmd	Cashless Exercise Of Options For Common Stock CashlessExerciseOfOptionsForCommonStock		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001553643

Files In Submission

Name	View Source	Status
0001213900-22-071154-index-headers.html	Edgar Link	pending
0001213900-22-071154-index.html	Edgar Link	pending
0001213900-22-071154.txt	Edgar Link	pending
0001213900-22-071154-xbrl.zip	Edgar Link	pending
f10q0922ex31-1_relmadatherap.htm	Edgar Link	pending
f10q0922ex31-2_relmadatherap.htm	Edgar Link	pending
f10q0922ex32-1_relmadatherap.htm	Edgar Link	pending
f10q0922ex32-2_relmadatherap.htm	Edgar Link	pending
f10q0922_relmadatherap.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
f10q0922_relmadatherap_htm.xml	Edgar Link	completed
rlmd-20220930_cal.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rlmd-20220930.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
rlmd-20220930_def.xml	Edgar Link	unprocessable
rlmd-20220930_lab.xml	Edgar Link	unprocessable
rlmd-20220930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RLMD
RELMADA THERAPEUTICS, INC. Stock $rlmd

2022 Q4 Form 10-Q Financial Statement

#000121390022071154 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RLMD RELMADA THERAPEUTICS, INC. Stock $rlmd

2022 Q4 Form 10-Q Financial Statement

#000121390022071154 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RLMD
RELMADA THERAPEUTICS, INC. Stock $rlmd